PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Azathioprine

Drugs in development · updated 30 October 2026

Azathioprine: clinical trials and development status

Other names and codes: Imuran, Jayempi

NLM verified identityApproved in the US (FDA)Authorised in the EU (EMA) since 21 June 2021

As of 30 October 2026 Azathioprine is in 17 active clinical trials (recruiting or ongoing, phases I–III) for 29 diseases. The most advanced phase is III.

17Active trials
IIIMost advanced phase
29Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Azathioprine and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov.

DiseaseMost advanced phaseActive trialsReference trial
Myelin Oligodendrocyte Glycoprotein Antibody-Associated DiseaseIII2NCT05545384
Rheumatoid arthritisIII2NCT03414502
Anti-neutrophil cytoplasmic antibody-associated vasculitisIII1NCT07168161
Autoimmune hepatitisII–III1NCT06650124
MyelitisIII1NCT05349006
Neuromyelitis opticaIII1NCT05349006
Optic neuritisIII1NCT05349006
Sickle-cell diseaseII2NCT04362293
VasculitisII2NCT06941376
Ankylosing spondylitisII1NCT07138898
Arthritis, JuvenileII1NCT07138898
ColitisII1NCT07619898
DermatomyositisII1NCT07138898
Giant cell arteritisII1NCT07138898
Granulomatosis with polyangiitisII1NCT07138898
HepatitisII1NCT07619898
IgA VasculitisII1NCT02939573
MelanomaII1NCT07619898
Polymyalgia rheumaticaII1NCT07138898
PolymyositisII1NCT07138898
Primary angiitis of the central nervous systemII1NCT07902492
Psoriatic arthritisII1NCT07138898
Relapsing polychondritisII1NCT06941376
Rheumatic DiseasesII1NCT07138898
SpondylarthritisII1NCT07138898
Systemic lupus erythematosusII1NCT07138898
Ulcerative colitisII1NCT06213857
VitiligoI1NCT07044141
PemphigusEarly I1NCT07769333

Everything on Azathioprine

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch